Amazon is launching RxPass within the US, a brand new drug subscription unique to Prime members that prices customers a $5 month-to-month payment to ship eligible prescription drugs to their doorstep. Introduced on Tuesday in a press release, the Amazon RxPass subscription program offers generic drugs to deal with over 80 widespread well being situations, together with hypertension, hair loss, nervousness, and acid reflux disease.
The $5 cost consists of the price of supply and is added to Prime clients’ present month-to-month subscription payment. The RxPass payment is a flat fee and doesn’t enhance even when customers require a number of prescriptions every month. Medicines will be delivered on both a month-to-month or quarterly foundation relying on the prescription necessities. Circumstances lined by the service additionally embrace allergy symptoms, diabetes (excluding insulin), and anemia. Amazon says that greater than 150 million People already take a number of of the drugs out there by way of RxPass. A full record of generic drugs lined by the RxPass subscription will be discovered on the Amazon pharmacy website.
Clients enrolled in authorities applications like Medicare and Medicaid will not be eligible for RxPass
Amazon has launched a number of healthcare providers lately. The corporate closed down its original Amazon Care telehealth program (launched in 2019) in November final yr in favor of its newer Amazon Clinic telehealth service. RxPass subscriptions dispense from Amazon Pharmacy — an reasonably priced on-line pharmacy unique to Prime members that launched in 2020.
The RxPass subscription service is obtainable right this moment in most US states. Amazon has not introduced any plans to increase the service outdoors of the US or if it should increase the record of medicines. Clients who’re enrolled in Medicare, Medicaid, or every other authorities well being care program will not be eligible for RxPass however can nonetheless use authorities insurance coverage to fill prescriptions at Amazon Pharmacy.